therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is an ultra-pure, EPA-only omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com.
If you are reporting an adverse event or product complaint, please email firstname.lastname@example.org or call the Amarin Call Center at 1-855-VASCEPA.
Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").
Who We Are
Alliances with complementary partners are important for maximizing our
success. Amarin seeks to be the ‘partner-of-choice’ for companies that
aim to develop and commercialize innovative products in the cardiovascular
and synergistic therapeutic areas.
» Learn More About Partnering With Amarin
Careers @ Amarin
Amarin’s greatest assets are Vascepa and its people. Attitude, effort and
ingenuity can accomplish great things and people who exemplify these traits
are the building blocks of Amarin’s success.
» View Career Opportunities
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.